

こころとからだに、
おいしいものを。



Offering delicious products
for sound mind and body



July 15, 2022

Company: DyDo Group Holdings, Inc.
Representative: Tomiya Takamatsu, President
(Code 2590 on the Tokyo Stock Exchange Prime Market)
Inquiries: Naokazu Hasegawa, Corporate Officer
and General Manager of Corporate Communication Department

Acquisition by a Consolidated Subsidiary of Marketing Licenses for Pharmaceuticals

DyDo Group consolidated subsidiary, DyDo Pharma, Inc. (hereafter “DyDo Pharma”), acquired a first-class marketing license for pharmaceuticals, second-class marketing license for pharmaceuticals, and a marketing license for Gene, Cellular, and Tissue-based Products from Osaka Prefecture, and the necessary procedures have been completed.

We have designated the healthcare-related market as our next growth area, including life science fields, which have high growth potential. Of those, we have focused on medications for challenging diseases that have fewer than 50,000 sufferers in the whole of Japan, so-called “orphan drugs.” In January 2019, we established DyDo Pharma to handle our orphan drug business. There are still many such orphan diseases for which there are no treatment options, and this is a social issue that needs to be addressed.

Taking this situation on board, DyDo Pharma has outlined the following corporate vision: We hope to help people lead a fuller life by developing and providing innovative medicines to fulfill unmet medical needs. The company is now working to develop drug treatments for rare congenital diseases and ultra-orphan diseases, for which there are very few sufferers.

The acquisition of these marketing licenses will allow more flexible development within the fields of pharmaceutical medicine and regenerative medicine products. DyDo Pharma will strive to make an even greater contribution to the world of medical care through its work with medicines and regenerative medicine products.

These acquisitions do not affect the forecast performance figures detailed in the FY2022 consolidated performance forecasts we announced on March 4, 2022.